When investigators retraced recurrent mutations, expression changes, and methylation shifts in hundreds of Wilms tumor case, they identified two main pathways.
The test, developed with Pfizer, could identify renal cancer patients who would experience recurrence, but not who would benefit from adjuvant Sutent.
The grant will fund a collaboration investigating whether genomic signatures and other biomarkers can be used in clinical diagnosis and monitoring of kidney cancer.
In PLOS this week: papillary renal cell carcinoma mutations, role of microRNAs in cold- and alkaline-adapted fish, and more.
The University of California, Los Angeles-led team said the approach outperformed two established classification methods.
In PLOS this week: Kashmiri ancestry analysis, genome-wide association study of gestational age, and more.
A renal cell carcinoma study revealed increased metabolic gene expression in PD-L1-positive tumors from individuals who did not respond to nivolumab.
The company plans to launch its first bladder cancer test in the second half of the year, and is in the early stages of validating a third test for prostate cancer.
Both institutions aim to develop novel liquid biopsy approaches that would improve physicians' ability to diagnose, monitor, and treat cancer patients.
A Baylor College of Medicine-led team uncovered nine genomic subtypes of kidney cancer that may help direct patients' treatments.
The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.
Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.
In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.
China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.